Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) reached a new 52-week high on Thursday . The stock traded as high as $37.50 and last traded at $37.2550, with a volume of 193976 shares changing hands. The stock had previously closed at $36.63.
Analyst Upgrades and Downgrades
ETON has been the topic of a number of research reports. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. B. Riley Financial increased their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. HC Wainwright boosted their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Finally, Zacks Research downgraded Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $41.00.
Read Our Latest Report on Eton Pharmaceuticals
Eton Pharmaceuticals Price Performance
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.05). The company had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%. Sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.75 earnings per share for the current year.
Insider Activity at Eton Pharmaceuticals
In other news, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Krempa sold 42,797 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the sale, the insider owned 25,249 shares of the company’s stock, valued at approximately $843,064.11. This trade represents a 62.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 150,000 shares of company stock valued at $4,853,921. Company insiders own 16.49% of the company’s stock.
Institutional Trading of Eton Pharmaceuticals
A number of institutional investors have recently bought and sold shares of ETON. Quarry LP bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth about $37,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $44,000. Legal & General Group Plc acquired a new stake in Eton Pharmaceuticals during the second quarter worth approximately $41,000. China Universal Asset Management Co. Ltd. bought a new stake in Eton Pharmaceuticals in the fourth quarter worth approximately $74,000. Finally, SG Americas Securities LLC acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at approximately $109,000. Institutional investors own 27.86% of the company’s stock.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.
The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.
Read More
- Five stocks we like better than Eton Pharmaceuticals
- MarketBeat Week in Review – 06/29 – 07/03
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
